e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Outcomes and new treatment strategies in pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry
H. Gall (Giessen, Germany)
Source:
International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension
Session:
Outcomes and new treatment strategies in pulmonary hypertension
Session type:
Poster Discussion
Number:
3534
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Gall (Giessen, Germany). Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry. 3534
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011
Safety of riociguat for chronic thromboembolic pulmonary hypertension (CTEPH): Interim data from a prospective non-interventional study in Japan
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry
Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Year: 2011
TOPP: the first international registry in pediatric pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
Interim analysis of pulmonary arterial hypertension (PAH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Incident pulmonary arterial hypertension in a Brazilian reference center: Results of a four-year registry
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
REVEAL: a contemporary US pulmonary arterial hypertension registry
Source: Eur Respir Rev 2012; 21: 8-18
Year: 2012
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Epidemiology of pulmonary hypertension: new data from the Swiss registry
Source: Eur Respir J 2006; 28: Suppl. 50, 545s
Year: 2006
Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Pulmonary arterial hypertension prototype for national protocol and registry
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Macitentan in pulmonary hypertension (PH): Data from OPUS and OrPHeUS real-world data sets
Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside
Year: 2019
Clinical characteristics of pulmonary arterial hypertension in Ireland: results of a national register
Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases
Year: 2008
Safety of macitentan in portopulmonary hypertension (PoPH): Real-world experience by liver transplant candidacy in the OPUS registry
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Year: 2020
CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study
Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models
Year: 2011
PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension
Source: Eur Respir J 2015; 45: 1314-1322
Year: 2015
Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept